trial · primary record
Dabogratinib (TYRA-300) 60mg
Low Grade Upper Tract Urothelial Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 285 |
| Primary completion | 2030-11 |
| Primary endpoint | To assess the efficacy of Dabogratinib in LG UTUC FGFR3+ participants (proportion of participants with a CR within 6 months out of all LG UTUC FGFR3+ participants) |
| Registry ID | NCT07265947 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:45:20.980Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07265947
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.